Nová voľba na liečbu neutropénie – lipegfilgrastim // SOLEN

Praktické lekárnictvo 1/2015

New option for the treatment of neutropenia − lipegfilgrastim

The cancer patients receiving chemotherapy have during therapy the occurrence of various complications. The most frequent complications include neutropenia (granulocytopenia) and febrile neutropenia which require rapid diagnostic and therapeutic steps. The consequences of febrile neutropenia can endanger the patient’s life and they can result in delays and dose reductions of chemotherapy. The principle of treatment of neutropenic patients is the immediate deployment of broad spectrum antibiotics after the relevant microbiological diagnostics. Two basic approaches are used most commonly for the prevention of febrile neutropenia : the primary antimicrobial prophylaxis and administration of growth factors (G-CSF).

Keywords: lipegfilgrastim, human growth factor (G-CSF), neutropenia.